Immune failure, infection and survival in chronic lymphocytic leukemia in Denmark by Andersen, Michael Asger & Niemann, Carsten Utoft
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Immune failure, infection and survival in chronic lymphocytic leukemia in Denmark
Andersen, Michael Asger; Niemann, Carsten Utoft
Published in:
Haematologica
DOI:
10.3324/haematol.2018.197889
Publication date:
2018
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Andersen, M. A., & Niemann, C. U. (2018). Immune failure, infection and survival in chronic lymphocytic
leukemia in Denmark. Haematologica, 103(7), e330-e330. https://doi.org/10.3324/haematol.2018.197889
Download date: 03. Feb. 2020
Immune failure, infection and survival in chronic
lymphocytic leukemia in Denmark
We are very thankful to Crassini et al. for evaluating the
impact of infections on overall survival (OS) in their long-
term follow-up cohort as a commentary to our paper on
predicting infection in CLL.1 They report a significant asso-
ciation between infection during the first year of observa-
tion and OS. In the last couple of years, our groups and
others have examined the immune dysfunction, both in
general but particularly hypogammaglobulinemia, in
patients with CLL. Both groups have demonstrated poor
survival among CLL patients with hypogammaglobuline-
mia. Now, Crassini et al. demonstrate that identifying
immune dysfunction in terms of early infection is predic-
tive of poor OS.
Within our nationwide cohort of patients diagnosed
with CLL in Denmark since 2008, we re-analyzed OS and
treatment free survival (TFS) based on whether patients
have had an infection during the first year after diagnosis
or not.2 All patients alive and treatment-naïve one year
after CLL diagnosis were included for this analysis. As
demonstrated below, the association (P<0.001) between
infection, OS and TFS, as reported by Crassini et al., could
be validated in this nationwide cohort (Figure 1 A and B).
When discussing immune dysfunction in CLL in the era
of targeted therapies, three important questions warrant
further assessment: 
i) Are we able to identify patients with immune dysfunc-
tion prior to significant morbidity or mortality due to
infections? The data presented in the original paper and in
the work by Crassini et al. contribute further to answering
this question; at EHA 2018, we present the first machine
learning based approach to identifying patients at high risk
of infection at diagnosis of CLL. 
ii) Are we able to change the microenvironmental inter-
action and thus the immune dysfunction in CLL by target-
ed agents? For ibrutinib, Sun et al. showed an increase in
IgA after 6 months of treatment and several publications
have demonstrated changes in microenvironmental inter-
action upon clinical use of ibrutinib.3-6 
iii) Most importantly, will we be able to change the nat-
ural history of CLL and thereby decrease morbidity and
mortality due to infections and immune dysfunction in
CLL? To address this question, we are currently develop-
ing a randomized clinical trial of pre-emptive treatment in
patients newly diagnosed with CLL, who are at high risk
of infection but do not meet the IWCLL indication for
treatment.
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Figure 1. Kaplan-Meier curves for A) overall survival and B) treatment free survival. (A) Kaplan-Meier curve from one year after diagnosis until death or end of
follow up for all included patients grouped by patients having an infection during the first year (red). (B) Kaplan-Meier curve from one year after diagnosis until
death, treatment or end of follow up for all included patients grouped by patients having an infection during the first year (red).
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